Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | 39 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Nov. 25, 2025 |
Apr. 30, 2023 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Dec. 31, 2025 |
|
| Milestone Payment Receivable | $ 3,370 | $ 3,370 | $ 3,370 | $ 3,724 | ||||
| Costs and Expenses | $ 28,455 | $ 32,354 | $ 55,769 | $ 67,323 | ||||
| PDE7 [Member] | National Institute on Drug Abuse (“NIDA”) [Member] | ||||||||
| Grants Receivable | $ 6,240 | |||||||
| Grants Receivable, Period | 3 years | |||||||
| Costs and Expenses | $ 2,300 | |||||||
| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Zaltenibart [Member] | ||||||||
| Proceeds from Sale of Productive Assets | $ 240,000 | |||||||
| Milestone Benchmark One, If Milestone Achieves | 510,000 | |||||||
| Milestone Benchmark Two, If Milestone Achieves | 1,300,000 | |||||||
| Milestone Payment Receivable | $ 2,100,000 | |||||||